硫酸吲哚酚对单核细胞趋化功能的影响及机制研究-内科学（肾病）专业毕业论文.docxVIP

第三军医大学硕士学位论文rpm 第三军医大学硕士学位论文 rpm Revolution per minute 每分钟转数 HPLC High performance liquid chromatography 高效液相色谱法 pg Microgram 微克 mg Milligram 毫克 THP．1 Human acute monocytic leukemia cell人急性单核细胞白血病细 line 胞系 ATCC American type culture collection 美国模式培养物集存库 ELISA Enzyme-linked immunoabsorbent assay 酶联免疫吸附试验 OD Optical density 光密度 Nanometer 纳米 C0， Carbon dioxide 二氧化碳 CCK．8 Cell Counting Kit-8 细胞计数试剂盒 H3P04 Phosphoric acid 磷酸 TMB Tetramethylbenzidine 四甲基联苯胺 D1 water Deionized Water 去离子水 HRP Horseradish peroxidase 辣根过氧化物酶 HA Hippuric acid 马尿酸 IA Indoleacetic acid 吲哚乙酸 ABCGl ATP．binding cassette transporters G1 ATP结合盒转运体G1 SR—B1 Scavenger receptor class B memberl B类1型清道夫受体 万方数据 第三军医大学硕士学位论文Effect 第三军医大学硕士学位论文 Effect of indoxyl sulfate on the chemotaxis of monocytes Abstract Background Chronic kidney disease(CKD)incidence increased year by year,affecting 1 0％of the population worldwide，is now viewed as part of the rising global non—communicable disease burden．With the progression of CKD，some patients will go into end—stage renal disease(ESRD)，need rely on blood purification therapy or a kidney transplant to maintain life．The retention of uremic toxins in ESRD patients，is the basic cause of uremic syndrome．The European uremic toxin work group(EUTox)divided those uremic toxins into three categories according to molecular weight and protein binding capacity：(1)Free water-soluble low—molecular—weight solutes(500Da)；(2)Protein—bound uremic toxins (PBUTs)；(3)the larger“middle molecules”(500Da)．Dialysis presents as the primary method for solute removal in ESRD patients．Present techniques allow for the removal of compounds up to～20 kDa(the majority of low and middle weight molecules)；however， albumin(66．5 kDa)bound solutes are unable to be dialytically cleared due to their augmented size． Uremic toxins is a major risk factor for cardiovascular disease(CVD)，and CVD is a common comorbidity and a major cause of mortality in ESRD patients，even when they enters the dialysis therapy．Thus